

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1 (canceled).

Claim 2 (currently amended): An antibody or binding fragment thereof which ~~specifically binds MCP-1 receptor polypeptide, wherein the polypeptide is selected from the group consisting of:~~

- (a) ~~a polypeptide comprising comprises the amino acid sequence of SEQ ID NO: 2;~~
- (b) ~~a polypeptide comprising the amino acid sequence of SEQ ID NO: 4; and~~
- (c) ~~a polypeptide encoded by an isolated nucleic acid selected from the group consisting of:~~
  - (i) ~~DNA comprising residues 40 through 1161 of the DNA sequence of SEQ ID NO:1~~
  - (ii) ~~DNA comprising residues 81 through 1160 of the DNA sequence of SEQ ID NO:3; and~~
  - (iii) ~~DNA that, due to the degeneracy of the genetic code, encodes a polypeptide, encoded by any of the foregoing DNA sequences.~~

Claims 3-8 (canceled).

Claim 9 (currently amended): The antibody of claim [[3]] 2, wherein the antibody is labeled with a detectable label.

Claim 10 (currently amended): The antibody of claim [[6]] 9, wherein the detectable label is a radioactive isotope.

Claim 11 (currently amended): The antibody of claim [[3]] 2, wherein the antibody is a monoclonal antibody.

Claim 12 (currently amended): The antibody of claim [[3]] 2, wherein the antibody is a humanized antibody.

Claim 13 (currently amended): A cell line producing the monoclonal antibody of claim [[8]] 11.

Claim 14 (currently amended): The cell line of claim [[10]] 13 that is a eucaryotic eukaryotic cell line.

Claim 15 (currently amended): The cell line of claim [[10]] 13 that is a prokaryotic prokaryotic cell line.

Claim 16 (currently amended): A method of making the antibody of claim 3 an antibody that binds MCP-1 receptor polypeptide comprising:

- (a) immunizing an animal with the polypeptide of claim 3 under conditions to elicit an antibody response comprising SEQ ID NO: 4;
- (b) isolating antibody-producing cells from the animal;
- (c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;

Appl. No. 09/625,573  
Amdt. dated September 26, 2003  
Reply to Office Action of June 30, 2003

PATENT

- (d) culturing the hybridoma cells; and
- (e) isolating from the culture monoclonal antibodies which ~~specifically~~ bind to the ~~polypeptide of claim 3~~ MCP-1 receptor polypeptide.

Claim 17 (currently amended): A composition comprising an antibody according to claim [[3]] 2, and a pharmaceutically acceptable carrier.

Claim 18 (canceled).

Claim 19 (currently amended): The antibody of claim [[3]] 2, wherein the ~~specific~~ binding of the antibody or the binding fragment to the MCP-1 receptor polypeptide results in neutralization of activity of the MCP-1 polypeptide.

Claim 20 (new): An antibody made by the method of claim 16.